COMPLETED

Glucose Frequent of A1GDM in Labor

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a prospective double arm study in patients with Gestational Diabetes Mellitus (GDM) utilizing frequent (single fingerstick on admission) vs infrequent glucose monitoring in labor (q 4 hours in latent labor and every 2 hours in active labor). Primary Objective: The primary outcome is glucose value of the neonate at birth. Secondary Objectives: Determine rates of insulin requirements within different monitoring techniques. Determine if there is a difference in neonatal intensive care unit (NICU) admission within different monitoring techniques. Determine neonatal blood glucose concentrations at 24 hours of life, number of glucose treatments, and neonatal hyperbilirubinemia. Secondary characteristics to be viewed for each diagnosis; BMI, race, age, and parity.

Official Title

Glucose Monitoring for A1GDM

Quick Facts

Study Start:2024-12-05
Study Completion:2025-05-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT06744621

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 51 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * All female patients of reproductive age (menarche-menopause: 18-51 years) who have the diagnosis diet controlled GDM
  2. * Patient with singleton gestation presenting in labor or for induction
  3. * Patients who had "good" glucose control and were A1GDM. Good Control;
  4. * - Patient with overall outpatient glucose average of less than 100
  5. * - No evidence of fetopathy, large for gestational age or polyhydramnios.
  6. * - Hgb A1c \<5.7
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Principal Investigator

Thomas Owens, MD
PRINCIPAL_INVESTIGATOR
Mount Sinai West

Study Locations (Sites)

Mount Sinai West
New York, New York, 10019
United States

Collaborators and Investigators

Sponsor: Icahn School of Medicine at Mount Sinai

  • Thomas Owens, MD, PRINCIPAL_INVESTIGATOR, Mount Sinai West

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12-05
Study Completion Date2025-05-30

Study Record Updates

Study Start Date2024-12-05
Study Completion Date2025-05-30

Terms related to this study

Additional Relevant MeSH Terms

  • Gestational Diabetes, Controlled by Diet